EMCDDA initial report on the new psychoactive substance 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC)
1-(3-Chlorophenyl)-2-(methylamino) propan-1-one (3-chloromethcathinone, 3-CMC) is a synthetic cathinone stimulant. It is a ring-substituted cathinone, which is structurally related to methcathinone and 4-chloromethcathinone (4-CMC).
The initial report is submitted to the Commission and the Member States.
The purpose of the initial report is to provide scientific evidence to the Commission to allow it to make an informed decision regarding whether or not there is a need to request a risk assessment on a new psychoactive substance as set out in Article 5c of Regulation (EC) No 1920/2006 (as amended).
Based on the information reported by the Network, on 9 September 2021, the EMCDDA assessed the existing information on 3-CMC, based on the following criteria:
-
reports of health problems;
-
reports of social problems;
-
reports of seized material;
-
pharmacological and toxicological properties and analogy with better-studied substances; and,
-
potential for further spread.
The EMCDDA concluded that the assessment gave rise to concerns that 3-CMC may pose health or social risks at Union level, and, consequently, determined that an initial report should be produced.
